This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

2024 ASCO® Annual Meeting Insights Hub
J

ASCO® 2024 Insights: "I-SPY2.2 Trial - Rates of pCR After Neoadjuvant Datopotamab Deruxtecan for High-Risk Stage 2/3 BC"

By 2024 ASCO® Annual Meeting Insights Hub FEATURING Jane Meisel
By 2024 ASCO® Annual Meeting Insights Hub FEATURING Jane Meisel
199 views
June 13, 2024

Chapters

I-SPY 2.2 Trial Design Overview

00:00

Dato-DXd Treatment Results & Future Plans

04:01

0 Comments
Login to view comments. Click here to Login

Featured Video

05:59
Lilly Medical Affairs

Progression on First-Line Therapy in HR+, HER2- MBC: Treatments and …

Feat. J. O’Shaughnessy

Featured Video

03:57
Lilly Medical Affairs

Resistance Mechanisms to ET, Including ESR1 Mutations in HR+, HER2- …

Feat. K. Jhaveri

2024 ASCO® Annual Meeting Insights Hub: Breast Videos

24:36
2024 ASCO® Annual Meeting Insights Hub

ASCO 2024 Highlights: Insights From Key Abstracts on mBC

Feat. S. Aithal
09:34
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Impact of ctDNA Surveillance on Clinical …

Feat. M. Lipsyc-Sharf
05:06
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Genomic Alterations in HR+/HER2- Metastat…

Feat. M. Bhave
View All

Related Content

AUTOPLAY
25:08
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Breast Cancer Highlights - Monday Morning Practice

Feat. S. Tolaney, H. Rugo
14:16
Dana-Farber Cancer Institute

Year in Review: Breast Cancer

Feat. P. Tarantino
09:55
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "The ABCs of ADCs - What Does the Future H…

Feat. E. Hamilton
05:43
Total Health

Neoadjuvant Chemo for HR+ BC: Year in Review

Feat. C. Ma
22:34
Dana-Farber Cancer Institute

What's New in Breast Cancer?

Feat. S. Tolaney
10:34
Sara Tolaney

ASCO® 2024 Noteworthy Abstracts in Breast Cancer

Feat. H. Rugo
36:18
Insights from ESMO Breast 2024 Annual Meeting

Metastatic Breast Cancer Comprehensive Review: ESMO Breast 2024 Awar…

Feat. H. Rugo
33:44
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Expert Recap: "Metastatic Breast Cancer Deep Dive &a…

Feat. S. Tolaney, H. Rugo
06:10
Insights from ESMO Breast 2024 Annual Meeting

ESMO Breast 2024 Summary: "Is There a Role for Combining ADCs W…

Feat. S. Tolaney
21:31
Insights from ESMO Breast 2024 Annual Meeting

ESMO Breast 2024 Summary: "Community Oncologists Highlights&quo…

Feat. S. Tolaney, H. Rugo
07:50
Oncology Data Advisor

ESMO 2023 Insights: "Real-World Use Patterns, Effectiveness, &a…

Feat. K. Kalinsky
13:47
Stanford Medicine

HR+ Advanced/Metastatic BC Treatment Options: Refining Endocrine Sen…

Feat. M. Dolezal
17:35
Insights from 2023 SABCS

SABCS 2023 Summary: "Top 5 Studies Including KATHERINE & HE…

Feat. P. Tarantino
10:09
Insights from ESMO Breast 2024 Annual Meeting

ESMO Breast 2024 Insights: "Pooled Analysis of T-DXd Retreatmen…

Feat. H. Rugo
05:35
Insights from ESMO Breast 2024 Annual Meeting

ESMO Breast 2024 Insights: "IMpassion132 Trial - Is There a Rol…

Feat. S. Tolaney
09:54
Insights from 2023 ESMO Annual Meeting

Adjuvant Abemaciclib + Endocrine Therapy for HR+, HER2- High-Risk eB…

Feat. J. Huober
30:46
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Panel Discussion: "Metastatic Breast Cancer"

Feat. S. Tolaney, H. Rugo
12:55
UChicago Medicine

Advances in Targeted and Endocrine Therapies for Metastatic HR+/HER2…

Feat. N. Chen
21:37
Dana-Farber Cancer Institute

Standard Treatments for HR+/HER2- mBC in 2023

Feat. S. Sammons
07:49
UChicago Medicine

Antibody Drug Conjugates: Overview and Background of a Revolution in…

Feat. H. Rugo